Can a Fatty Liver Affect Your Eyes?

Fatty liver disease can affect your eyes through a combination of metabolic disruption, systemic inflammation and the conditions that commonly accompany it. Formally known as metabolic dysfunction-associated steatotic liver disease (MASLD), fatty liver is closely linked to type 2 diabetes, high blood pressure and dyslipidaemia, all of which carry independent risks for eye complications. When these conditions occur together, the risk is compounded. This article explains which eye problems are associated with liver disease, how fat accumulation in the liver can damage other organs, which symptoms to watch for, and how fatty liver is diagnosed and managed on the NHS.

Can a fatty liver really affect your eyes?

Yes, fatty liver disease can affect the eyes through metabolic disruption and the systemic conditions that accompany it, including type 2 diabetes, high blood pressure and dyslipidaemia, with risk increasing as liver disease advances.

Yes, fatty liver disease can affect the eyes, both directly through metabolic changes and indirectly through the systemic conditions that often accompany it. Fatty liver disease, formally known as metabolic dysfunction-associated steatotic liver disease (MASLD), is closely linked to obesity, type 2 diabetes, high blood pressure and dyslipidaemia.^[1][2] Each of these conditions independently carries a risk of eye complications, and when they occur together alongside liver disease, that risk is compounded.

The liver plays a central role in regulating lipid metabolism, glucose homeostasis and the processing of fat-soluble vitamins, including vitamin A. When the liver is damaged or functioning poorly, these processes are disrupted in ways that can have downstream effects on ocular health. Research published in peer-reviewed journals has identified associations between MASLD and several eye conditions, though these associations are largely observational and a direct causal link has not been established for all of them.

It is important to note that fatty liver disease itself is a spectrum. Simple steatosis (fat accumulation without significant inflammation) carries a different risk profile from metabolic dysfunction-associated steatohepatitis (MASH), which involves inflammation and can progress to fibrosis and cirrhosis. The more advanced the liver disease, the greater the potential for systemic complications, including those affecting the eyes. Understanding this connection can help patients and clinicians take a more holistic approach to monitoring and management.

Which eye problems are linked to liver disease?

Diabetic retinopathy, dry eye disease, scleral icterus, xanthelasma and hypertensive retinopathy are all associated with fatty liver disease and the metabolic syndrome that frequently accompanies it.

Several eye conditions have been associated with fatty liver disease and the metabolic syndrome that frequently accompanies it. The most clinically significant include:

• Diabetic retinopathy: Because MASLD and type 2 diabetes are closely intertwined, diabetic retinopathy is one of the most common eye complications seen in this patient group. Retinopathy involves damage to the blood vessels of the retina. The NHS Diabetic Eye Screening Programme classifies it as background, pre-proliferative or proliferative retinopathy, and as diabetic maculopathy where the macula is affected; the risk of vision loss is considerably higher in more advanced stages.^[7][8]

• Dry eye disease: Some studies have found a higher prevalence of dry eye in people with MASLD, possibly related to altered lipid composition in the tear film and systemic inflammation. The evidence is observational and mixed, and this association should be interpreted with caution.

• Jaundice-related scleral icterus: In advanced liver disease or cirrhosis, bilirubin accumulates in the blood and can cause yellowing of the whites of the eyes (scleral icterus), which is a visible sign of significant liver dysfunction.^[12]

• Xanthelasma: Fatty deposits around the eyelids, known as xanthelasma, can occur when blood lipid levels are elevated, a common finding in people with fatty liver disease and dyslipidaemia.^[13] A lipid profile should be checked if xanthelasma are present.

• Hypertensive retinopathy: High blood pressure, which frequently co-exists with MASLD, can damage retinal blood vessels over time.

The evidence base for some of these associations is still developing, and researchers continue to investigate the precise mechanisms. The overlap between liver disease and metabolic risk factors means that eye health monitoring is a clinically relevant consideration for this patient group.

How does fat build-up in the liver damage other organs?

Fat overload in liver cells triggers systemic inflammation, dyslipidaemia and insulin resistance, which damage blood vessels throughout the body, including the fine capillaries of the retina.

Fat accumulation in the liver triggers a cascade of metabolic and inflammatory processes that extend well beyond the liver itself. When hepatocytes (liver cells) become overloaded with fat, they are thought to release pro-inflammatory cytokines, reactive oxygen species and altered lipoproteins into the bloodstream. This systemic low-grade inflammation is proposed as a key driver of damage to distant organs, including the eyes, kidneys, heart and blood vessels, though the precise mechanisms continue to be investigated.

The liver is also responsible for producing proteins that regulate blood clotting, transporting vitamins and clearing toxins. In MASLD, these functions can become impaired. Reduced clearance of lipids leads to dyslipidaemia, characterised by elevated triglycerides and low HDL cholesterol, which promotes atherosclerosis and microvascular damage throughout the body. The retinal vasculature, being composed of very fine capillaries, is considered particularly vulnerable to this kind of damage.

Insulin resistance, which is both a cause and a consequence of fatty liver disease, further compounds the problem. Elevated insulin and glucose levels are thought to damage endothelial cells lining blood vessels, impairing their ability to regulate blood flow and maintain vascular integrity. This mechanism is central to the development of diabetic retinopathy and other microvascular complications.

Vitamin A metabolism is another important consideration. The liver stores and processes vitamin A, which is essential for maintaining the photoreceptor cells in the retina. In advanced liver disease, vitamin A deficiency can develop, potentially contributing to night blindness and other visual disturbances. This is more commonly seen in cirrhosis than in early-stage fatty liver disease. If you are concerned about vitamin A deficiency, speak to your GP or specialist before taking any supplements: high-dose vitamin A can itself be harmful to the liver and should not be taken without clinical supervision.

What eye symptoms should prompt you to see a doctor?

Sudden floaters, flashes of light or a curtain-like shadow across your vision require same-day urgent assessment; yellowing of the whites of the eyes should also be reviewed promptly.

Anyone with known fatty liver disease, metabolic syndrome or type 2 diabetes should be alert to changes in their vision and seek prompt medical advice if they occur. The following symptoms warrant a consultation with your GP or optometrist:

• Blurred or fluctuating vision, which can be an early sign of retinal changes or blood sugar instability

• Yellowing of the whites of the eyes (scleral icterus), which may indicate significant liver dysfunction and should be assessed promptly

• Dry, gritty or irritated eyes that are persistent and not explained by environmental factors

• Floaters, flashes of light or a sudden loss of part of your visual field, which can indicate retinal problems and require urgent assessment

• Fatty deposits or lumps around the eyelids (xanthelasma), which should be reviewed alongside a lipid profile

• Difficulty seeing in low light or at night, which may suggest vitamin A deficiency in the context of advanced liver disease

If you experience a sudden increase in floaters, flashes of light or a curtain-like shadow across your visual field, contact your local optometrist for same-day urgent assessment, as they can examine the retina and refer you directly to eye casualty if needed. You can also contact NHS 111 for urgent advice or attend an eye casualty department promptly, as these symptoms can indicate a retinal detachment or other sight-threatening emergency. For a life-threatening emergency such as sudden loss of vision with severe headache or neurological symptoms, call 999 immediately.

Routine eye examinations are recommended at least every two years by the NHS, and people with diabetes are invited for annual diabetic eye screening through the NHS Diabetic Eye Screening Programme.^[10][11] If you have fatty liver disease alongside diabetes or other metabolic risk factors, attending these appointments is particularly important.

How is fatty liver diagnosed and managed on the NHS?

NICE guidance (NG49) recommends liver function tests, ultrasound and non-invasive fibrosis scoring such as FIB-4, with management centred on lifestyle change and treatment of associated metabolic risk factors.

Fatty liver disease is typically identified through a combination of blood tests, imaging and clinical assessment on the NHS. Liver function tests (LFTs) may show elevated enzymes such as ALT and AST, though these can be normal even in the presence of significant steatosis. An ultrasound scan of the abdomen is the most commonly used first-line imaging tool and can detect fat accumulation in the liver, though it cannot reliably stage the degree of fibrosis.

NICE guidance (NG49) recommends that people with suspected MASLD are assessed for fibrosis using a non-invasive scoring tool such as the FIB-4 index or the NAFLD Fibrosis Score as an initial step.^[17] Where the result is indeterminate or suggests significant fibrosis, an Enhanced Liver Fibrosis (ELF) test may be used, as recommended by NICE diagnostic guidance (DG34), to help determine whether referral to hepatology is needed.^[17][18] A FibroScan (transient elastography) or MRI may also be used to assess the degree of fibrosis in secondary care. People with scores or results indicating advanced fibrosis should be referred to a hepatologist for further assessment.

NICE guidance also recommends that people with MASLD are assessed for associated metabolic risk factors, including type 2 diabetes, hypertension and dyslipidaemia. Management is primarily lifestyle-based: NICE NG49 supports a sustained reduction in body weight as a target to reduce liver fat and inflammation, with a loss of around 7 to 10 per cent of body weight associated with histological improvement in clinical studies. This is achieved through a combination of dietary modification and increased physical activity.

For people with type 2 diabetes and fatty liver disease, certain glucose-lowering medications, including GLP-1 receptor agonists, have shown benefits for liver-related outcomes in clinical trials. It is important to note that these medicines are not currently licensed in the UK specifically for the treatment of MASLD or MASH; any liver-related benefits observed in trials are thought to be largely mediated through weight loss and improved glycaemic control.^[23][24] Prescribing decisions are made on an individual basis by the treating clinician, and local Integrated Care Boards (ICBs) determine which treatments are commissioned for NHS use in their area.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, for those exploring their options alongside NHS care. Where a weight-management medicine is considered appropriate following a consultation, a prescriber will review eligibility before any prescription is issued. Regular monitoring of liver function, metabolic parameters and eye health remains central to long-term management, and patients are encouraged to maintain open communication with their GP or specialist team about any new or changing symptoms.

Frequently Asked Questions